p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer
Menée à partir de données portant sur 273 témoins et 146 patientes ayant reçu un diagnostic de carcinome canalaire in situ, cette étude analyse l'association entre un immunomarquage positif des protéines p16, COX-2 et/ou Ki67 et le risque de cancer du sein invasif ipsilatéral ultérieur
Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited.In a case–control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC.There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38–3.54).p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS.p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.
Cancer Epidemiology, Biomarkers & Prevention , article en libre accès 2025